Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.62)
# 194
Out of 5,124 analysts
117
Total ratings
55.14%
Success rate
34.39%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.61 | +272.67% | 3 | Dec 2, 2025 | |
| KOD Kodiak Sciences | Maintains: Buy | $24 → $26 | $27.96 | -7.01% | 7 | Nov 17, 2025 | |
| IMUX Immunic | Maintains: Buy | $10 → $8 | $0.53 | +1,398.97% | 6 | Nov 14, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $36.29 | +54.31% | 13 | Nov 12, 2025 | |
| FBLG FibroBiologics | Maintains: Buy | $10 → $5 | $0.22 | +2,123.21% | 7 | Nov 5, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $16.59 | +56.72% | 11 | Oct 31, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Buy | $30 → $44 | $36.31 | +21.18% | 5 | Oct 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $81.88 | +7.47% | 2 | Oct 20, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $7.96 | +50.75% | 7 | Aug 15, 2025 | |
| LYRA Lyra Therapeutics | Reiterates: Neutral | $16 | $3.08 | +419.48% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $16.00 | +250.00% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.01 | +298.01% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $5.83 | +71.53% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.18 | +93.05% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $22.62 | +41.47% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $7.50 | +380.00% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $455.28 | -93.85% | 1 | Aug 22, 2023 |
Akebia Therapeutics
Dec 2, 2025
Reiterates: Buy
Price Target: $6
Current: $1.61
Upside: +272.67%
Kodiak Sciences
Nov 17, 2025
Maintains: Buy
Price Target: $24 → $26
Current: $27.96
Upside: -7.01%
Immunic
Nov 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $0.53
Upside: +1,398.97%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $36.29
Upside: +54.31%
FibroBiologics
Nov 5, 2025
Maintains: Buy
Price Target: $10 → $5
Current: $0.22
Upside: +2,123.21%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $16.59
Upside: +56.72%
Zenas BioPharma
Oct 28, 2025
Maintains: Buy
Price Target: $30 → $44
Current: $36.31
Upside: +21.18%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $81.88
Upside: +7.47%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $7.96
Upside: +50.75%
Lyra Therapeutics
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $3.08
Upside: +419.48%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $16.00
Upside: +250.00%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $2.01
Upside: +298.01%
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $5.83
Upside: +71.53%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.18
Upside: +93.05%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $22.62
Upside: +41.47%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $7.50
Upside: +380.00%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $455.28
Upside: -93.85%